Real-world data can improve feasibility planning, but it should be paired with site feedback, patient burden review, and early recruitment metrics before teams make enrollment assumptions.
In this guide
Key points
- Real-world data can help pressure-test eligibility, geography, routine care patterns, and screening assumptions.
- Database counts do not prove patients are reachable, interested, eligible, or near a capable site.
- Sponsors should combine real-world data with site feedback, records-readiness planning, and early funnel evidence.
Real-world data can help, but it is not magic
FDA describes real-world data as data relating to patient health status or healthcare delivery collected from sources such as electronic health records, claims, registries, and digital health technologies.
Used carefully, real-world data can improve feasibility planning. Used carelessly, it can create false confidence before a study ever opens.
Where real-world data can help
Real-world data can support early planning questions: how common key eligibility criteria appear in routine care, which geographic areas may have more relevant patient populations, what comorbidities or medication patterns may affect eligibility, and how often patients receive tests needed for screening.
It can also reveal whether a protocol depends on procedures that are routine in some settings but unusual in others. That matters because a patient who exists in a database may still be difficult to screen if records, labs, or site access are not practical.
Where it can mislead
Real-world data may be incomplete, inconsistent, or collected for billing and care rather than research. A database may show that patients exist, but not that they are reachable, interested, eligible, or near a capable site.
A better approach pairs real-world data with site feedback, patient burden review, and operational screening metrics. That combination helps teams distinguish theoretical prevalence from recruitable opportunity.
Use a tactical workflow
Start with the protocol's must-have criteria, pressure-test those criteria against real-world data, ask sites which criteria will create screening friction, review whether required procedures are routine or unusual, and use early recruitment data to adjust outreach and site support.
For example, a sponsor may estimate strong eligibility using claims data. After launch, sites may report that many patients lack a required recent lab result. The rescue plan is not simply more advertising. It is workflow repair: clarify lab windows, support record collection, and adjust prescreening language.
Where TrialsNest fits
TrialsNest can help connect planning assumptions to what happens after launch: source quality, prescreening status, records blockers, scheduling movement, screen failures, and close reasons.
That gives sponsors a way to compare real-world planning assumptions against actual site workflow evidence.
Sources used for this playbook
FDA Real-World Evidence: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
FDA Framework for Real-World Evidence Program: https://www.fda.gov/media/120060/download
Sources and editorial notes
Published .
This guide explains recruitment work and questions to discuss with your team.
This information is educational. Your study team makes medical, eligibility, and enrollment decisions.
See TrialsNest in action
Bring this workflow into one place.
Manage inquiries, follow-ups, records, and visits. Keep sponsors updated on progress.
Sponsor portfolio
39 / 50 enrolled78%
74 / 120 enrolled62%
9 / 10 enrolled90%
Keep reading
Clinical trial diversity planning before recruitment opens
A practical guide to clinical trial diversity planning through protocol review, site selection, logistics, and early enrollment measurement.
Patient group engagement before the protocol is locked
A case-study style guide to using patient group input before protocol, visit, and recruitment workflow decisions become difficult to change.
Sponsor recruitment reporting guides and templates
Resources for sponsor and CRO teams comparing clinical trial recruitment reporting software, dashboard views, site blockers, source quality, and next actions.
Rescue planning for an under-enrolling clinical trial
Under-enrollment should be diagnosed before teams increase advertising spend. The constraint may be source quality, site follow-up, records blockers, eligibility ambiguity, visit burden, or sponsor decision lag.
